News

Arun Upadhyay, PhD, discusses new study findings from trials of OCU400 (Ocugen)

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.

PST-611 is a first in class non-viral vectorized therapy for the treatment of dry AMD/GA coding for human transferrin.

Atsena Therapeutics and Nippon Shinyaku have formed an exclusive licensing agreement for ATSN-101, a gene therapy for Leber congenital amaurosis (LCA1). Nippon Shinyaku will commercialize ATSN-101 in the U.S. and Japan, while Atsena retains global rights outside these territories.

Study highlights safety, efficacy of device in managing persistent DED.

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need for improved awareness, cost-effectiveness, and integration to increase diabetic retinopathy screening rates.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora.

The weekly drug-eluting contact lens was created by the company’s proprietary 3D printing technology and met all primary endpoints with no serious adverse events reported in either cohort.

The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD).

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD).

Harrow announced that starting in January 2025, Vevye will be covered under key Medicare Part D formularies and across major insurance programs, expanding access to the dry eye disease treatment for millions of patients, particularly older adults.

Analysis highlights discrepancies between adult, pediatric cataract procedures.

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables detailed 3D visualization of choroidal vessels from OCT scans. This technique could improve diagnostics for retinal diseases like macular degeneration, offering a safer alternative to traditional methods.

New analysis brings disease progression and therapeutics into focus

Katherine Talcott, MD, discussed other potential therapies and their mechanisms of action being evaluated in clinical trials at the OSN New York 2024 conference.

Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy.

This Week in Ophthalmology is a weekly video series highlighting some of the top articles featured on the Ophthalmology Times website.

The company noted that its GalOmic pipeline includes ETX-407 for the treatment of dry age-related macular degeneration (AMD).

A $6.4 million grant over 5 years from the National Institutes of Health’s National Eye Institute was awarded conduct drug development work and investigational new drug (IND)-enabling toxicology studies.

Ferhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that promotes blood vessel growth. Combining anti-VEGF with an experimental drug targeting HIF-1 could enhance vision outcomes and prevent vision loss.

Following oculoplastic surgery, patients who underwent aromatherapy had shorter stays in the post-anesthesia care unit

The Eye Care Network team was on site to share key data and interview presenters at the annual meeting held in Chicago, Illinois.

The meeting is set to take place from November 8 to 10, 2024 at the Sheraton Times Square Hotel in New York City.

Omar Salamanca, MD, staff ophthalmologist, Orbis Flying Eye Hospital, discusses Orbis's tailored glaucoma training programs, which focus on hands-on surgical skills, early detection, telemedicine, and personalized follow-up care, helping underserved regions improve glaucoma management and blindness prevention.

Scientists at Scripps Research and its nonprofit drug development arm, the Calibr-Skaggs Institute for Innovative Medicines, are working to advance regenerative medicines capable of repairing tissues damaged by age-related disease